Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 124

1.

Primary large cell neuroendocrine carcinoma of the skin: An under-recognized entity and a mimic of metastatic disease.

Lano IM, Rayson D, Arnason T, Walsh NMG.

J Cutan Pathol. 2017 Sep 28. doi: 10.1111/cup.13051. [Epub ahead of print]

PMID:
28960456
2.

To The Last Drop.

Rayson D.

J Clin Oncol. 2017 Sep 10;35(26):3083-3084. doi: 10.1200/JCO.2017.73.9326. Epub 2017 Jun 19. No abstract available.

PMID:
28628365
3.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators.

N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. Erratum in: N Engl J Med. 2017 Aug 17;377(7):702.

PMID:
28581356
4.

Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.

Pritchard KI, Chia SK, Simmons C, McLeod D, Paterson A, Provencher L, Rayson D.

Oncologist. 2017 Jan;22(1):12-24. doi: 10.1634/theoncologist.2016-0185. Epub 2016 Nov 18.

PMID:
27864574
5.

Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.

Younis T, Rayson D, Jovanovic S, Skedgel C.

Breast Cancer Res Treat. 2016 Oct;159(3):425-32. doi: 10.1007/s10549-016-3954-1. Epub 2016 Aug 30. Review.

PMID:
27572552
6.

Decision-making by surgeons about referral for adjuvant therapy for patients with non-small-cell lung, breast or colorectal cancer: a qualitative study.

Urquhart R, Kendell C, Buduhan G, Rayson D, Sargeant J, Johnson P, Grunfeld E, Porter GA.

CMAJ Open. 2016 Jan 12;4(1):E7-E12. doi: 10.9778/cmajo.20150030. eCollection 2016 Jan-Mar.

7.

Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid.

Yan M, Ho C, Winquist E, Jonker D, Rayson D, Stitt L, Tokmakejian S, Tomiak A, Vincent MD.

Clin Colorectal Cancer. 2016 Dec;15(4):369-376.e3. doi: 10.1016/j.clcc.2016.06.001. Epub 2016 Jun 23.

PMID:
27474080
8.

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.

Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, Johnson C, Lemieux J, Paterson I, Sebag IA, Simmons C, Sulpher J, Thain K, Thavendiranathan P, Wentzell JR, Wurtele N, Côté MA, Fine NM, Haddad H, Hayley BD, Hopkins S, Joy AA, Rayson D, Stadnick E, Straatman L.

Can J Cardiol. 2016 Jul;32(7):831-41. doi: 10.1016/j.cjca.2016.02.078. Epub 2016 Apr 7. Review.

PMID:
27343741
9.

Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus.

Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R, Mete O, Pasieka J, Rivera J, Wong R, Segelov E, Rayson D.

Cancer Treat Rev. 2016 Jun;47:32-45. doi: 10.1016/j.ctrv.2016.05.003. Epub 2016 May 17. Review.

PMID:
27236421
10.

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.

Rayson D, Lupichuk S, Potvin K, Dent S, Shenkier T, Dhesy-Thind S, Ellard SL, Prady C, Salim M, Farmer P, Allo G, Tsao MS, Allan A, Ludkovski O, Bonomi M, Tu D, Hagerman L, Goodwin R, Eisenhauer E, Bradbury P.

Breast Cancer Res Treat. 2016 May;157(1):109-16. doi: 10.1007/s10549-016-3812-1. Epub 2016 Apr 26.

PMID:
27116183
11.

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study.

Iqbal J, Nussenzweig A, Lubinski J, Byrski T, Eisen A, Bordeleau L, Tung NM, Manoukian S, Phelan CM, Sun P, Narod SA; Hereditary Breast Cancer Research Group.

Br J Cancer. 2016 May 10;114(10):1160-4. doi: 10.1038/bjc.2016.58. Epub 2016 Mar 17.

12.

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.

Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S, Dent S, Gelmon K, Paterson A, Rayson D, Berry DA.

JAMA Oncol. 2016 Jun 1;2(6):751-60. doi: 10.1001/jamaoncol.2015.6113.

PMID:
26914222
13.

White Knuckling.

Rayson D.

J Clin Oncol. 2016 Apr 20;34(12):1419-20. doi: 10.1200/JCO.2015.65.8419. Epub 2016 Feb 16. No abstract available.

PMID:
26884561
14.

Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.

Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.

Fertil Steril. 2016 Mar;105(3):781-785. doi: 10.1016/j.fertnstert.2015.11.034. Epub 2015 Dec 14.

PMID:
26698676
15.

Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?

Semple J, Metcalfe KA, Lubinski J, Huzarski T, Gronwald J, Armel S, Lynch HT, Karlan B, Foulkes W, Singer CF, Neuhausen SL, Eng C, Iqbal J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2015 Nov;154(1):163-9.

PMID:
26467043
16.

Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.

Lamond NW, Skedgel C, Rayson D, Younis T.

Curr Oncol. 2015 Aug;22(4):e246-53. doi: 10.3747/co.22.2383.

17.

Investigations for patients with early-stage breast cancer: oversetting the stage.

Rayson D, Porter G.

CMAJ. 2015 Sep 8;187(12):860-1. doi: 10.1503/cmaj.150621. Epub 2015 Jun 22. No abstract available.

18.

Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

Skedgel C, Rayson D, Younis T.

Support Care Cancer. 2016 Jan;24(1):387-94. doi: 10.1007/s00520-015-2805-7. Epub 2015 Jun 17.

PMID:
26081595
20.

Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.

Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA; Hereditary Breast Cancer Study Group.

Fam Cancer. 2015 Sep;14(3):383-91. doi: 10.1007/s10689-015-9798-8.

Supplemental Content

Loading ...
Support Center